Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics
Abstract
Background & Aims: Intravenous silibinin (SIL) is a potent antiviral agent against hepatitis C virus (HCV) genotype-1. In this study, we tested: (i) whether interferon-alfa (IFN)-free treatment with SIL plus ribavirin (RBV) can achieve sustained virological response (SVR); (ii) whether SIL is safe and feasible for prolonged duration of treatment and (iii) whether mathematical modelling of early on-treatment HCV kinetics can guide duration of therapy to achieve SVR. Methods: A 44 year-old female HCV-(genotype-1)-infected patient who developed severe psychiatric adverse events to a previous course of pegIFN+RBV, initiated combination treatment with 1200 mg/day of SIL, 1200 mg/day of RBV and 6000 u/day vitamin D. Blood samples were collected frequently till week 4, thereafter every 1–12 weeks until the end of therapy. The standard biphasic mathematical model with time-varying SIL effectiveness was used to predict the duration of therapy to achieve SVR. Results: Based on modelling the observed viral kinetics during the first 3 weeks of treatment, SVR was predicted to be achieved within 34 weeks of therapy. Provided with this information, the patient agreed to complete 34 weeks of treatment. IFN-free treatment with SIL+RBV was feasible, safe and achieved SVR (week-33). Conclusions: We report, for the first time, the usemore »
- Authors:
-
- Loyola Univ. Medical Center, Maywood IL (United States). Division of Hepatology; Los Alamos National Lab. (LANL), Los Alamos, NM (United States). Theoretical Biology and Biophysics
- Share'e Zedek Medical Center, Jerusalem (Israel). Digestive Disease Inst.
- Share'e Zedek Medical Center, Jerusalem (Israel). Digestive Disease Inst., Liver Unit
- Loyola Univ. Medical Center, Maywood IL (United States). Division of Hepatology
- Rottapharm Madaus, Monza (Italy)
- Share'e Zedek Medical Center, Jerusalem (Israel). Nursing Division
- Share'e Zedek Medical Center, Jerusalem (Israel). Internal medicine
- Publication Date:
- Research Org.:
- Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
- Sponsoring Org.:
- USDOE; National Institutes of Health (NIH)
- OSTI Identifier:
- 1282055
- Alternate Identifier(s):
- OSTI ID: 1321740
- Report Number(s):
- LA-UR-14-23527
Journal ID: ISSN 1478-3223
- Grant/Contract Number:
- AC52-06NA25396; R01-AI078881; P20-GM103452
- Resource Type:
- Accepted Manuscript
- Journal Name:
- Liver International
- Additional Journal Information:
- Journal Volume: 35; Journal Issue: 2; Journal ID: ISSN 1478-3223
- Publisher:
- Wiley
- Country of Publication:
- United States
- Language:
- English
- Subject:
- 60 APPLIED LIFE SCIENCES; 59 BASIC BIOLOGICAL SCIENCES; hepatitis C; individualized therapy; interferon-free treatment; mathematical modelling; silibinin; sustained virological response; viral kinetics; mathematical modeling
Citation Formats
Dahari, Harel, Shteingart, Shimon, Gafanovich, Inna, Cotler, Scott J., D'Amato, Massimo, Pohl, Ralf T., Weiss, Gali, Ashkenazi, Yaakov J., Tichler, Thomas, Goldin, Eran, and Lurie, Yoav. Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics. United States: N. p., 2014.
Web. doi:10.1111/liv.12692.
Dahari, Harel, Shteingart, Shimon, Gafanovich, Inna, Cotler, Scott J., D'Amato, Massimo, Pohl, Ralf T., Weiss, Gali, Ashkenazi, Yaakov J., Tichler, Thomas, Goldin, Eran, & Lurie, Yoav. Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics. United States. https://doi.org/10.1111/liv.12692
Dahari, Harel, Shteingart, Shimon, Gafanovich, Inna, Cotler, Scott J., D'Amato, Massimo, Pohl, Ralf T., Weiss, Gali, Ashkenazi, Yaakov J., Tichler, Thomas, Goldin, Eran, and Lurie, Yoav. Fri .
"Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics". United States. https://doi.org/10.1111/liv.12692. https://www.osti.gov/servlets/purl/1282055.
@article{osti_1282055,
title = {Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics},
author = {Dahari, Harel and Shteingart, Shimon and Gafanovich, Inna and Cotler, Scott J. and D'Amato, Massimo and Pohl, Ralf T. and Weiss, Gali and Ashkenazi, Yaakov J. and Tichler, Thomas and Goldin, Eran and Lurie, Yoav},
abstractNote = {Background & Aims: Intravenous silibinin (SIL) is a potent antiviral agent against hepatitis C virus (HCV) genotype-1. In this study, we tested: (i) whether interferon-alfa (IFN)-free treatment with SIL plus ribavirin (RBV) can achieve sustained virological response (SVR); (ii) whether SIL is safe and feasible for prolonged duration of treatment and (iii) whether mathematical modelling of early on-treatment HCV kinetics can guide duration of therapy to achieve SVR. Methods: A 44 year-old female HCV-(genotype-1)-infected patient who developed severe psychiatric adverse events to a previous course of pegIFN+RBV, initiated combination treatment with 1200 mg/day of SIL, 1200 mg/day of RBV and 6000 u/day vitamin D. Blood samples were collected frequently till week 4, thereafter every 1–12 weeks until the end of therapy. The standard biphasic mathematical model with time-varying SIL effectiveness was used to predict the duration of therapy to achieve SVR. Results: Based on modelling the observed viral kinetics during the first 3 weeks of treatment, SVR was predicted to be achieved within 34 weeks of therapy. Provided with this information, the patient agreed to complete 34 weeks of treatment. IFN-free treatment with SIL+RBV was feasible, safe and achieved SVR (week-33). Conclusions: We report, for the first time, the use of real-time mathematical modelling of HCV kinetics to individualize duration of IFN-free therapy and to empower a patient to participate in shared decision making regarding length of treatment. Lastly, SIL-based individualized therapy provides a treatment option for patients who do not respond to or cannot receive other HCV agents and should be further validated.},
doi = {10.1111/liv.12692},
journal = {Liver International},
number = 2,
volume = 35,
place = {United States},
year = {Fri Oct 10 00:00:00 EDT 2014},
month = {Fri Oct 10 00:00:00 EDT 2014}
}
Web of Science
Works referenced in this record:
Hepatitis C virus: Here comes all-oral treatment
journal, March 2014
- Dugum, M.; O'Shea, R.
- Cleveland Clinic Journal of Medicine, Vol. 81, Issue 3
Is the HCV Pipeline Heading in the Right Direction?
journal, March 2013
- Aronsohn, Andrew; Muir, Andrew J.; Swan, Tracy
- Gastroenterology, Vol. 144, Issue 3
Silibinin Is a Potent Antiviral Agent in Patients With Chronic Hepatitis C Not Responding to Pegylated Interferon/Ribavirin Therapy
journal, November 2008
- Ferenci, Peter; Scherzer, Thomas–Matthias; Kerschner, Heidrun
- Gastroenterology, Vol. 135, Issue 5
Understanding silibinin’s modes of action against HCV using viral kinetic modeling
journal, May 2012
- Guedj, Jeremie; Dahari, Harel; Pohl, Ralf T.
- Journal of Hepatology, Vol. 56, Issue 5
Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period
journal, March 2013
- Mariño, Zoe; Crespo, Gonzalo; D’Amato, Massimo
- Journal of Hepatology, Vol. 58, Issue 3
Silymarin for HCV infection
journal, January 2013
- Polyak, Stephen J.; Oberlies, Nicholas H.; Pécheur, Eve-Isabelle
- Antiviral Therapy, Vol. 18, Issue 2
A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure
journal, May 2010
- Snoeck, E.; Chanu, P.; Lavielle, M.
- Clinical Pharmacology & Therapeutics, Vol. 87, Issue 6
Modelling how ribavirin improves interferon response rates in hepatitis C virus infection
journal, December 2004
- Dixit, Narendra M.; Layden-Almer, Jennifer E.; Layden, Thomas J.
- Nature, Vol. 432, Issue 7019
Individualized treatment for patients with low HCV load (Genotype 1): A viral kinetic approach
journal, April 2014
- Dahari, Harel; Cotler, Scott J.
- Hepatology, Vol. 59, Issue 6
Vitamin D: An innate antiviral agent suppressing hepatitis C virus in human hepatocytes
journal, October 2011
- Gal-Tanamy, Meital; Bachmetov, Larisa; Ravid, Amiram
- Hepatology, Vol. 54, Issue 5
Classical and Emerging Roles of Vitamin D in Hepatitis C Virus Infection
journal, November 2011
- Gutierrez, Julio; Parikh, Neil; Branch, Andrea
- Seminars in Liver Disease, Vol. 31, Issue 04
Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients
journal, January 2011
- Abu-Mouch, Saif
- World Journal of Gastroenterology, Vol. 17, Issue 47
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon- Therapy
journal, October 1998
- Neumann, A. U.
- Science, Vol. 282, Issue 5386
Mathematical Modeling of HCV Infection and Treatment
book, January 2009
- Dahari, Harel; Shudo, Emi; Ribeiro, Ruy M.
- Hepatitis C
Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy
journal, January 2014
- Canini, Laetitia; DebRoy, Swati; Mariño, Zoe
- Antiviral Therapy, Vol. 20, Issue 2
Visualizing Hepatitis C Virus Infections in Human Liver by Two-Photon Microscopy
journal, October 2009
- Liang, Yuqiong; Shilagard, Tuya; Xiao, Shu–Yuan
- Gastroenterology, Vol. 137, Issue 4
Intravenous silibinin as ‘rescue treatment’ for on-treatment non-responders to pegylated interferon/ribavirin combination therapy
journal, January 2011
- Rutter, Karoline; Scherzer, Thomas-Matthias; Beinhardt, Sandra
- Antiviral Therapy, Vol. 16, Issue 8
Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy
journal, June 2010
- Neumann, U. P.; Biermer, M.; Eurich, D.
- Journal of Hepatology, Vol. 52, Issue 6
Is genotype 3 of the hepatitis C virus the new villain?: Hepatology
journal, April 2014
- Goossens, Nicolas; Negro, Francesco
- Hepatology, Vol. 59, Issue 6
Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection
journal, June 2012
- Aghemo, Alessio; Bhoori, Sherrie; nicola, Stella De
- Hepatitis Monthly, Vol. 12, Issue 6
Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection
journal, February 2013
- Polyak, Stephen J.; Ferenci, Peter; Pawlotsky, Jean-Michel
- Hepatology, Vol. 57, Issue 3
Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV–HCV coinfected patient
journal, October 2010
- Payer, B. A.; Reiberger, T.; Rutter, K.
- Journal of Clinical Virology, Vol. 49, Issue 2
Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C
journal, March 2011
- Beinhardt, Sandra; Rasoul-Rockenschaub, Susanne; Scherzer, Thomas Matthias
- Journal of Hepatology, Vol. 54, Issue 3
Silibinin mode(s) of action against hepatitis C virus: A controversy yet to be resolved
journal, June 2011
- Dahari, Harel; Guedj, Jeremie; Perelson, Alan S.
- Hepatology, Vol. 54, Issue 2
Silymarin Inhibits In Vitro T-Cell Proliferation and Cytokine Production in Hepatitis C Virus Infection
journal, February 2010
- Morishima, Chihiro; Shuhart, Margaret C.; Wang, Chia C.
- Gastroenterology, Vol. 138, Issue 2
Amanita poisoning: Treatment and the role of liver transplantation
journal, January 1989
- Klein, Andrew S.; Hart, John; Brems, John J.
- The American Journal of Medicine, Vol. 86, Issue 2
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C
journal, August 2005
- Zeuzem, Stefan; Pawlotsky, Jean-Michel; Lukasiewicz, Esther
- Journal of Hepatology, Vol. 43, Issue 2
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
journal, February 2013
- Guedj, J.; Dahari, H.; Rong, L.
- Proceedings of the National Academy of Sciences, Vol. 110, Issue 10
Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: Implications for treatment duration
journal, May 2011
- Guedj, Jeremie; Perelson, Alan S.
- Hepatology, Vol. 53, Issue 6
Hepatitis C can be cured globally, but at what cost?
journal, July 2014
- Hill, A.; Cooke, G.
- Science, Vol. 345, Issue 6193
Works referencing / citing this record:
A Parameter Estimation Method for Multiscale Models of Hepatitis C Virus Dynamics
journal, July 2019
- Reinharz, Vladimir; Churkin, Alexander; Lewkiewicz, Stephanie
- Bulletin of Mathematical Biology, Vol. 81, Issue 10
Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir/asunaprevir
journal, July 2019
- Huang, Chung‐Feng; Yeh, Ming‐Lun; Huang, Ching‐I
- Journal of Gastroenterology and Hepatology, Vol. 35, Issue 1
Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis
journal, December 2018
- Gambato, Martina; Canini, Laetitia; Lens, Sabela
- Liver International, Vol. 39, Issue 5
Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection
journal, June 2015
- Ke, Ruian; Loverdo, Claude; Qi, Hangfei
- PLOS Computational Biology, Vol. 11, Issue 6
Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
journal, January 2017
- Federico, Alessandro; Dallio, Marcello; Loguercio, Carmelina
- Molecules, Vol. 22, Issue 2
Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin
journal, July 2019
- Lhomme, Sebastien; DebRoy, Swati; Kamar, Nassim
- Viruses, Vol. 11, Issue 7
HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients
journal, December 2017
- Canini, Laetitia; Imamura, Michio; Kawakami, Yoshiiku
- PLOS ONE, Vol. 12, Issue 12
A Robust and Efficient Numerical Method for RNA-Mediated Viral Dynamics
journal, October 2017
- Reinharz, Vladimir; Churkin, Alexander; Dahari, Harel
- Frontiers in Applied Mathematics and Statistics, Vol. 3
Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
journal, January 2017
- Federico, Alessandro; Dallio, Marcello; Loguercio, Carmelina
- Molecules, Vol. 22, Issue 2